Eli Lilly has sued six US companies accused of selling illegal versions of its experimental weight-loss drug retatrutide, even though the highly anticipated treatment has not yet been approved by regulators or launched to the public.
The extraordinary legal crackdown comes as demand for next-generation obesity medicines fuels an underground market for products claiming to contain sought-after drugs.
Lilly says the alleged sellers are marketing unapproved retatrutide outside clinical trials, putting consumers at risk while potentially undermining the pharmaceutical giant's control over one of its most closely watched future treatments.
Retatrutide is still an investigational medicine and is legally available only to participants in Lilly-sponsored clinical trials. It has not been approved by the US Food and Drug Administration or any other regulatory agency.
That has not stopped an alleged black market from developing around the drug, forcing Lilly to take legal action before it can even officially reach patients.
Lilly Takes Legal Action as Demand Surges
The company filed six lawsuits on 12 August against Aesthetic Envy Cosmetic Centers, Astra LLC, Legendary Peptides, Striker Pharmacy, Texas Peptides and Lone Star Peptide Co, accusing them of illegally selling or promoting products represented as retatrutide.
Lilly has also referred more than 200 individuals and entities to US regulators, law enforcement agencies, state attorneys general, and professional licensing boards over alleged unauthorised sales.
The company says consumers should be particularly wary of products purchased outside legitimate clinical trials because there is no guarantee they contain the stated ingredient, the correct dose, or even a safe substance.
Dr. David Hyman, Lilly's chief medical officer, issued a blunt warning about the products being sold online.
'What is being sold on the black market is not a medicine–it is entirely unverified, unapproved and not worth the risk,' he said.
Lilly's concerns come amid a wider surge in demand for injectable and other prescription weight-loss treatments, creating lucrative opportunities for sellers attempting to capitalise on consumers eager to access the next big obesity drug.
The company is urging online marketplaces, social media platforms, payment processors, shipping companies, and regulators to help shut down unauthorised sales.
Why Retatrutide Is Already So Highly Sought After
Retatrutide has attracted enormous attention because it works differently from conventional GLP-1 medicines.
The once-weekly injection is a first-in-class triple hormone receptor agonist that activates GIP, GLP-1, and glucagon receptors. Lilly is studying it for obesity, type 2 diabetes, and several obesity-related conditions.
Recent Phase 3 results have intensified interest. In July, Lilly reported that participants with obesity or overweight and type 2 diabetes lost up to an average of 49.6lbs, or 20.8%, after 80 weeks in the TRIUMPH-2 trial.
In another Phase 3 study involving people with severe obesity and established cardiovascular disease, participants lost up to an average of 55.8lbs, or 22.6%, over the same period.
In May, Lilly reported even larger average weight loss in its TRIUMPH-1 trial, with participants taking the highest dose losing an average of 70.3lbs, or 28.3% after 80 weeks.
These are trial results reported by Lilly and do not mean the drug has been approved or established as safe and effective for general public use.
Lilly plans to submit a Biologics License Application to the FDA in the first quarter of 2027. Until regulators review the application and grant approval, retatrutide remains an experimental treatment rather than a commercially available weight-loss medicine.
That distinction is at the heart of Lilly's legal campaign. While the company is still working towards regulatory approval, it is already fighting to prevent unauthorised versions of its future drug from reaching consumers.
For anyone tempted by an online offer promising retatrutide ahead of its official launch, Lilly's warning is clear: a product claiming to contain the experimental drug may not be the real thing, and its safety, purity, or dosage cannot be guaranteed.
